735.35MMarket Cap-14.92P/E (TTM)
7.990High7.460Low1.25MVolume7.800Open7.910Pre Close9.61MTurnover1.47%Turnover RatioLossP/E (Static)96.63MShares19.09052wk High9.96P/B645.41MFloat Cap7.39052wk Low--Dividend TTM84.81MShs Float43.600Historical High--Div YieldTTM6.70%Amplitude0.710Historical Low7.688Avg Price1Lot Size
Avadel Pharmaceuticals Stock Forum
LUMRYZ Sales Surge 158% as Avadel Pharmaceuticals Eyes Cash Flow Positive 2025
AVDL fell 25.2% to $8 shortly before 5 p.m. ET after the company announced that Q4 revenues will come in at $50 million – below the $52.7 million that analysts had reportedly expected.
The company like...
yeah, cluster buys drew my attention too
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challen...
🎃⚡️🎃
📊⚡️📊
4 mins ago
Avadel Pharmaceuticals Announces FDA Approval of Lumryz™ (Sodium Oxybate) Extended-Release Oral Suspension (Ciii) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older With Narcolepsy
No comment yet